Skip to main content
Clinical Trials/NCT05165979
NCT05165979Active, not recruitingNot Applicable

Cohort Study for the Assessment of Long-term Impact of COVID-19 Among Moderate and Severe COVID-19 Patients in Brazil

Hospital Moinhos de Vento24 sites in 1 country650 target enrollmentStarted: December 21, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
650
Locations
24
Primary Endpoint
One-year utility score of health related quality of life

Study Overview

Brief Summary

The present prospective cohort study aims to assess factors associated with of one-year health-related quality of life and physical, cognitive and mental health outcomes among adult survivors of hospitalization for COVID-19. Adult patients requiring hospitalization due to COVID-19 disease will be followed through structured and centralized telephone interviews performed at 3, 6, 9 and 12 months after enrollment.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥18 years;
  • Symptomatic COVID-19 disease within the last 14 days;
  • Positive polymerase chain reaction (PCR) test for SARS-CoV-2 within the last 14 days;
  • Need of hospitalization (duration ≥ 48 hours).

Exclusion Criteria

  • Severe comorbidity with life expectancy less than 3 months;
  • Death during hospitalization;
  • Absence of telephone contact;
  • Absence of proxy for patients with communication difficulties;
  • Refusal or withdrawal of agreement to participate;
  • Previous enrollment in the study.

Outcomes

Primary Outcomes

One-year utility score of health related quality of life

Time Frame: The outcome will be assessed 12 months after enrollment.

The outcome will be assessed using the Brazilian version of the Euroqol-5D-3L (EQ-5D3L) questionnaire.

Secondary Outcomes

  • Instrumental Activities of Daily Living(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
  • Utility score of health related quality of life at 3, 6, and 9 months(The outcome will be assessed at 3, 6, and 9 months after enrollment.)
  • Incidence of major cardiovascular events(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
  • Prevalence of anxiety and depression symptoms(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
  • Incidence of rehospitalizations(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
  • Prevalence of prolonged COVID-19 symptoms(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
  • Prevalence of posttraumatic stress disorder symptoms(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
  • Incidence of return to work or study(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
  • Incidence of all-cause mortality(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
  • Prevalence of cognitive dysfunction(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
  • Incidence of new symptomatic COVID-19 infection(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
  • Physical functional status(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (24)

Loading locations...

Similar Trials